Dejan Juric and Peter Fasching to Explore CDK4/6 Inhibition in Breast Cancer – SPCC
Dejan Juric and Peter Fasching /LinkedIn

Dejan Juric and Peter Fasching to Explore CDK4/6 Inhibition in Breast Cancer – SPCC

SPCC (Sharing Progress in Cancer Care), an organization dedicated to advancing cancer care through education and scientific collaboration, shared on LinkedIn:

“How does CDK4/6 inhibition influence tumour biology across early and advanced HR+/HER2− breast cancer?

From cellular senescence and dormancy to recurrence and immune modulation, understanding the underlying mechanisms is vital to optimising combination endocrine therapies and emerging oral SERDs.

  • Join us live for “Tumour biology beyond CDK4/6”: 23 November, 14:30 CET.

Led by discussant Dejan Juric (Massachusetts General Hospital Cancer Center) and expert speaker Peter Fasching (University Hospital Erlangen and Comprehensive Cancer Center), this session bridges preclinical insights with clinical data to inform everyday treatment decisions.

Claim your spot on OncoCorner: Register for the webinar

This activity is supported by unrestricted funding from Novartis.”

Dejan Juric and Peter Fasching to Explore CDK4/6 Inhibition in Breast Cancer – SPCC

About CDK4/6 Inhibition and Emerging Breast Cancer Treatment Strategies

The upcoming SPCC OncoCorner webinar, scheduled for November 23, 2026, at 14:30 CET, will examine the biological and clinical implications of CDK4/6 inhibition in hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer.

CDK4/6 inhibitors, including palbociclib, ribociclib and abemaciclib, have become important components of endocrine-based treatment for advanced breast cancer and selected patients with high-risk early-stage disease.

These therapies work by interfering with cell-cycle progression, helping prevent cancer cells from proliferating. However, treatment resistance and disease recurrence remain important challenges, encouraging further research into tumour dormancy, cellular senescence and alternative molecular pathways.

Emerging approaches include next-generation CDK inhibitors and oral selective estrogen receptor degraders (SERDs), which are being investigated to improve treatment outcomes and address endocrine resistance. Research is also exploring how tumour biology and molecular biomarkers could help guide the selection and sequencing of targeted therapies.

Dejan Juric and Peter Fasching to Explore CDK4/6 Inhibition in Breast Cancer – SPCC